- E-postkenneth.dickstein@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2024). Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). European Journal of Heart Failure.
- (2024). Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF. International Journal of Cardiology.
- (2022). Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population. Turk Kardiyoloji Dernegi Arsivi. 182-191.
- (2022). The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health. 310-320.
- (2022). Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients With coronary artery disease and type 2 diabetes. Journal of the American Heart Association (JAHA).
- (2022). Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. European Journal of Heart Failure. 645-652.
- (2022). Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure). European Journal of Heart Failure. 1020-1029.
- (2022). Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care. 2152-2155.
- (2022). Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal. 4469-4479.
- (2022). Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure. 308-320.
- (2022). Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research (CVR). 2478-2487.
- (2022). Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure. JACC. Heart failure. 623-632.
- (2022). Multimarker profiling identifies protective and harmful immune processes in heart failure: Findings from BIOSTAT-CHF. Cardiovascular Research (CVR). 1964-1977.
- (2022). Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Failure. 4167-4176.
- (2022). Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology. 85-90.
- (2022). Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal. 2224-2234.
- (2022). Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. European Journal of Heart Failure. 1239-1248.
- (2022). Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure. 13 sider.
- (2022). Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle.
- (2022). Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure. 9 sider.
- (2022). Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology.
- (2022). Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC. Heart failure. 415-427.
- (2022). Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Failure. 1-12.
- (2022). Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. European Journal of Heart Failure. 43-51.
- (2022). Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. American Society of Nephrology. Clinical Journal. 228-239.
- (2021). Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: Insights from the high-risk myocardial infarction database. European Heart Journal: Acute Cardiovascular Care. 127-131.
- (2020). Cardiac resynchronization therapy in Romania – results from the european society of cardiology CRT survey II. Revista română de cardiologie. 48-55.
- (2019). Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. Circulation: Heart Failure. 1-13.
- (2019). Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure. 1-11.
- (2019). Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology. 1215-1225.
- (2019). Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. American Heart Journal. 83-90.
- (2019). Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care. 231-241.
- (2019). Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology. 29-40.
- (2019). Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients with Heart Failure: Results from the DEFINE-HF and BIOSTAT-CHF Studies. JAMA cardiology.
- (2019). Contemporary practice of CRT implantation in scandinavia compared to Europe. Scandinavian Cardiovascular Journal. 9-13.
- (2019). Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. European Journal of Heart Failure. 218-226.
- (2019). Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. Europace. 918-927.
- (2019). Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. European Journal of Heart Failure.
- (2018). Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. International Journal of Cardiology. 260-266.
- (2018). Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal. 4269-4276.
- (2018). Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology. 1081-1090.
- (2018). CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? European Journal of Heart Failure. 1039-1051.
- (2018). Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 323-331.
- (2017). Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology. 2490-2500.
- (2017). Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Circulation: Heart Failure.
- (2017). Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association (JAHA). 1-29.
- (2017). Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure. 673-681.
- (2017). Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: A subanalysis of the randomized EchoCRT trial. European Heart Journal. 720-726.
- (2017). Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. European Journal of Heart Failure. 1284-1293.
- (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction: The BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal. 2936-2943.
- (2017). Highly increased Troponin i levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise Study (NEEDED) 2013. European Journal of Preventive Cardiology (EJPC). 885-894.
- (2017). Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. International Journal of Cardiology. 274-281.
- (2017). Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine. 1956-1964.
- (2017). Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. European Journal of Heart Failure. 80-87.
- (2017). Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure. 627-634.
- (2017). Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study. European Heart Journal. 1883-1890.
- (2017). Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology. 722-733.
- (2017). Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 271-279.
- (2017). A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. European Journal of Heart Failure. 635-642.
- (2017). 'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. European Journal of Heart Failure. 1447-1454.
- (2016). What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. European Journal of Heart Failure. 66-70.
- (2016). What constitutes optimal neurohumoral antagonism in chronic heart failure? Heart. 1922-1932.
- (2016). Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine.
- (2016). Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia. American Journal of Cardiology. 1482-1487.
- (2016). Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization. European Journal of Heart Failure. 1499-1505.
- (2016). Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology. 1771-1778.
- (2016). Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Circulation: Arrhythmia and Electrophysiology.
- (2016). Circulating galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology. 398-405.
- (2016). Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: A subgroup analysis of the EchoCRT trial. European Heart Journal. 49-59.
- (2016). Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine. 1521-1532.
- (2016). Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology. 1444-1455.
- (2016). A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. European Journal of Heart Failure. 716-726.
- (2015). The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. European Journal of Heart Failure. 329-339.
- (2015). The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: A subgroup analysis of the EchoCRT trial. European Heart Journal. 1983-1989.
- (2015). The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure. 1075-1083.
- (2015). Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 1144-1151.
- (2015). Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure. 544-548.
- (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 631-638.e7.
- (2015). Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal. 290-297.e1.
- (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine. 2247-2257.
- (2015). International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): Rationale for and design of a global registry. European Journal of Heart Failure. 527-533.
- (2015). Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: The rationale, design and methodology of the HF-Wii study; A multicentre randomized controlled trial. European Journal of Heart Failure. 743-748.
- (2015). Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: Design of the multicentre randomized e-Vita heart failure trial. European Journal of Heart Failure. 1310-1316.
- (2014). The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. European Heart Journal. 395-402.
- (2014). The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure. 289-299.
- (2014). The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. European Heart Journal: Acute Cardiovascular Care. 46-55.
- (2014). Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial. European Journal of Preventive Cardiology (EJPC).
- (2014). Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. International Journal of Cardiology. 360-367.
- (2014). Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). Circulation. 958-965.
- (2014). Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality findings from ASCEND-HF. Circulation: Heart Failure. 918-925.
- (2014). European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace. 137-141.
- (2013). Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology. 1094-1101.
- (2013). Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. European Journal of Heart Failure. 1419-1428.
- (2013). Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 1267-1276.
- (2013). Global variation in quality of care among patients hospitalized with acute heart failure in an international trial findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circulation. Cardiovascular Quality and Outcomes. 534-542.
- (2011). The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. International Journal of Cardiology. 277-282.
- (2010). The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. International Journal of Cardiology. 228-233.
- (2009). The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction. American Journal of Cardiology. 1179-1183.
- (2009). Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure A Comparative Analysis on Clinical and Prognostic Insights. Circulation: Heart Failure. 549-555.
- (2009). Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 1084-1091.
- (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal. 1331-1339.
- (2009). Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. European Journal of Heart Failure. 1143-1151.
- (2009). Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2436-2448.
- (2009). Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 1840-1848.
- (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 1187-1194.
- (2009). C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal. 1180-1186.
- (2009). B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. International Journal of Cardiology. 358-362.
- (2008). Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. European Journal of Heart Failure. 140-148.
- (2008). Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. International Journal of Cardiology. 117-120.
- (2008). Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure. 899-906.
- (2008). A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure. 89-95.
- (2007). Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. American Journal of Cardiology. 647-650.
- (2007). Unrecognized glycometabolic disturbance as measured by hemoglobin A(1c) is associated with a poor outcome after acute myocardial infarction. American Heart Journal. 470-476.
- (2006). The impact of morbid events on survival following hospitalization for complicated myocardial infarction. European Journal of Heart Failure. 74-80.
- (2006). The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. European Journal of Heart Failure. 628-633.
- (2006). Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal. 927e1-927e6.
- (2005). Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1117.
- (2005). Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. American Journal of Medicine. 752-758.
- (2005). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAL experience. European Heart Journal. 350-356.
- (2005). Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. Journal of Cardiac Failure. 492-497.
- (2005). Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? Nature Clinical Practice Cardiovascular Medicine. 440-441.
- (2005). Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 650-61.
- (2005). Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy. 275-286.
- (2005). Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal. 123-131.
- (2004). The data monitoring experience in the MOXCON trial. European Heart Journal. 174-178.
- (2004). Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
- (2004). Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
- (2004). Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology. 632-636.
- (2003). Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
- (2000). The use of angiotensin II receptor antagonists in heart failure. Tidsskrift for Den norske legeforening. 817-821.
- (2000). The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
- (2000). Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
- (2000). Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. European Heart Journal. 584.
- (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. Circulation. 609.
- (2000). Pharmacotherapy following myocardial infarction - a review of current treatment practices. Exp Opin Pharmacother. 1105-1116.
- (2000). Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
- (2000). Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. European Heart Journal. 464.
- (2000). Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
- (2000). Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
- (2000). Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. European Journal of Heart Failure. In press.
- (2000). Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 17-20.
- (2000). Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. European Heart Journal. 234.
- (2000). Are emergency medical admissions dependent on the weather? Tidsskrift for Den norske legeforening. 355-357.
- (2000). Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
- (1993). The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. International Journal of Cardiology. 37-45.
Vitenskapelig foredrag
- (2008). C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction.
- (2005). Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre.
- (2002). The role of angiotensin II antagonists in heart failure and following myocardial infarction.
- (2002). State of the art management of myocardial infarction.
- (2002). Results of recent trials in patients with heart failure following myocardial infarction.
- (2002). Outpatient heart failure management programs 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure.
- (2002). Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions.
- (2002). Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial.
- (2002). Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial.
- (2002). Clinical implications of losartan in the OPTIMAAL study.
- (2002). Beta-blockers should be withdrawn in decompensated heart failure patients.
- (2002). Angiotensin II antagonists; are they established therapy in heart failure?
- (2002). ARBs are as good as ACE inhibitors.
- (2001). Effect of exercise training on muscle fibre characteristics in patients with heart failure.
- (1996). N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis.
Sammendrag/abstract
- (2013). The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. European Heart Journal. 349-349.
- (2013). Early discharge (< 3 days) following primary PCI is safe in low risk patients. European Heart Journal. 246-246.
- (2013). ESC Heart Failure Guidelines 2012-a review. Journal of Cardiac Failure. S106-S107.
- (2010). Smokers spend shorter time in hospital than non-smokers following complicated AMI. European Heart Journal. 683-683.
- (2010). Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure. S73-S74.
- (2010). Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). European Heart Journal. 604-604.
- (2010). NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. European Heart Journal. 514-515.
- (2010). Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. European Heart Journal. 314-314.
- (2010). Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. European Heart Journal. 233-233.
- (2010). Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. European Heart Journal. 192-193.
- (2010). Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circulation. 2217-2217.
- (2009). Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. Circulation. S818-S818.
- (2007). The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. European Journal of Heart Failure. 10-11.
- (2004). What's new in the management of heart failure? Atherosclerosis Supplements.
- (2004). Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. Circulation. A1032-A1032.
- (2004). The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. European Heart Journal. 599-599.
- (2004). The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. European Heart Journal.
- (2004). Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. European Heart Journal. 292-292.
- (2004). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. European Heart Journal. 299-299.
- (2004). Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. JACC. 1153-1173.
- (2004). Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. Circulation. 574-575.
- (2004). Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 305-305.
- (2004). Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. European Heart Journal.
- (2003). Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. Circulation.
- (2003). Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. Circulation. 692-692.
Vitenskapelig oversiktsartikkel/review
- (2020). 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 407-477.
- (2019). Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. The Lancet. 1045-1055.
- (2016). Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology. 408-413.
- (2015). The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology. 256-264.
- (2013). Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 1082-1094.
- (2012). The High-Risk Myocardial Infarction Database Initiative. Progress in cardiovascular diseases. 362-366.
- (2010). Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure. 423-433.
- (2008). Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure. 1229-1235.
- (2008). Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure. 201-213.
- (2008). Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska. S389-S454.
- (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2388-442.
- (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 933-989.
- (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2388-2442.
- (2007). Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 684-694.
- (2005). Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. European Journal of Heart Failure. 303-308.